Adipokines: A novel link between adiposity and carotid plaque vulnerability

European Journal of Clinical Investigation

Volumn 42, Issue 12, 2012, Pages 1278-1286

  Kadoglou, Nikolaos P E ^a   Sailer, Nikolaos ^a   Moumtzouoglou, Anestis ^a   Kapelouzou, Alkistis ^b   Gerasimidis, Thomas ^c   Kostakis, Alkiviadis ^b   Liapis, Christos D ^d  

^a Aristotle University of Thessaloniki   (Greece)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Apelin; Carotid atherosclerosis; Carotid plaque vulnerability; Gray scale median score; Statins; Visfatin

Indexed keywords

ACETYLSALICYLIC ACID; ADIPOCYTOKINE; ANTIHYPERTENSIVE AGENT; APELIN; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CLOPIDOGREL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BODY MASS; CAROTID ARTERY OBSTRUCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; SCORING SYSTEM; SYSTOLIC BLOOD PRESSURE; TITRIMETRY; TREATMENT INDICATION;

ADIPOSITY; AGED; ANTICHOLESTEREMIC AGENTS; BODY MASS INDEX; CHOLESTEROL, LDL; CYTOKINES; FEMALE; HEPTANOIC ACIDS; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY; PLAQUE, ATHEROSCLEROTIC; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PYRROLES; RISK FACTORS; ULTRASONOGRAPHY, DOPPLER, COLOR;

EID: 84869874592     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2012.02728.x     Document Type: Article

References (35)

1. Kadoglou NP, Avgerinos ED, Liapis CD. An update on markers of carotid atherosclerosis in patients with Type 2 diabetes. Biomark Med 2010;4:601-9.
2. Tasci I, Erdem G, Ozgur G, Tapan S, Dogru T, Genc H et al. LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia. Atherosclerosis 2009;204:222-8.
3. Kadoglou NP, Tsanikidis H, Kapelouzou A, Vrabas I, Vitta I, Karayannacos PE et al. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus. Metabolism 2010;59:373-9.
4. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998;251:471-6.
5. Szczepanska-Sadowska E, Cudnoch-Jedrzejewska A, Ufnal M, Zera T. Brain and cardiovascular diseases: common neurogenic background of cardiovascular, metabolic and inflammatory diseases. J Physiol Pharmacol 2010;61:509-21.
6. Kleinz MJ, Davenport AP. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept 2004;118:119-25.
7. Kadoglou NP, Lampropoulos S, Kapelouzou A, Gkontopoulos A, Theofilogiannakos EK, Fotiadis G et al. Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease - KOZANI STUDY. Transl Res 2010;155:238-46.
8. Ognjanovic S, Bryant-Greenwood GD. Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes. Am J Obstet Gynecol 2002;187:1051-8.
9. Kadoglou NP, Sailer N, Moumtzouoglou A, Kapelouzou A, Tsanikidis H, Vitta I et al. Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2010;118:75-80.
10. Aust G, Uptaite-Patapoviene M, Scholz M, Richter O, Rohm S, Blüher M. Circulating Nampt and RBP4 levels in patients with carotid stenosis undergoing carotid endarterectomy (CEA). Clin Chim Acta 2011;412:1195-200.
11. Dahl TB, Yndestad A, Skjelland M, Øie E, Dahl A, Michelsen A et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007;115:972-80.
12. Lardizabal JA, Deedwania P. Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease. Cardiol Clin 2011;29:87-103.
13. Kadoglou NPE, Gerasimidis T, Kapelouzou A, Moumtzouoglou A, Avgerinos ED, Karayannacos PE et al. Beneficially changes of serum calcification markers and contralateral carotid plaques echogenicity after combined carotid artery stenting plus intensive lipid-lowering therapy in patients with bilateral carotid stenosis. Eur J Vasc Endovasc Surg 2010;39:258-65.
14. Watanabe K, Sugiyama S, Kugiyama K, Honda O, Fukushima H, Koga H et al. Stabilization of carotid atheroma assessed by quantitative ultrasound analysis in nonhypercholesterolemic patients with coronary artery disease. J Am Coll Cardiol 2005;46:2022-30.
15. Kadoglou NP, Gerasimidis T, Moumtzouoglou A, Kapelouzou A, Sailer N, Fotiadis G et al. Intensive lipid-lowering therapy ameliorates novel calcification markers and GSM score in patients with carotid stenosis. Eur J Vasc Endovasc Surg 2008;35:661-8.
16. Kasner SE. Clinical interpretation and use of stroke scales. Lancet Neurol 2006;5:603-12.
17. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
18. Grant EG, Benson CB, Moneta GL, Alexandrov AV, Baker JD, Bluth EI et al. Carotid artery stenosis: gray-scale and Doppler US diagnosis - Society of Radiologists in Ultrasound Consensus Conference. Radiology 2003;229:340-6.
19. Rittig K, Hildebrandt U, Thamer C, Staiger H, Peter A, Stefan N et al. Apelin serum levels are not associated with early atherosclerosis or fat distribution in young subjects with increased risk for type 2 diabetes. Exp Clin Endocrinol Diabetes 2011;119:358-61.
20. Chun HJ, Ali ZA, Kojima Y, Kundu RK, Sheikh AY, Agrawal R et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest 2008;118:3343-54.
21. Kuklinska AM, Sobkowicz B, Sawicki R, Musial WJ, Waszkiewicz E, Bolinska S et al. Apelin: a novel marker for the patients with first ST-elevation myocardial infarction. Heart Vessels 2010;25:363-7.
22. Halvorsen B, Otterdal K, Dahl TB, Skjelland M, Gullestad L, Øie E et al. Atherosclerotic plaque stability - what determines the fate of a plaque? Prog Cardiovasc Dis 2008;51:183-94.
23. Pitkin SL, Maguire JJ, Kuc RE, Davenport AP. Modulation of the apelin/APJ system in heart failure and atherosclerosis in man. Br J Pharmacol 2010;160:1785-95.
24. Leeper NJ, Tedesco MM, Kojima Y, Schultz GM, Kundu RK, Ashley EA et al. Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation. Am J Physiol Heart Circ Physiol 2009;296:H1329-35.
25. Przewlocka-Kosmala M, Kotwica T, Mysiak A, Kosmala W. Reduced circulating apelin in essential hypertension and its association with cardiac dysfunction. J Hypertens 2011;29:971-9.
26. Chandrasekaran B, Kalra PR, Donovan J, Hooper J, Clague JR, McDonagh TA. Myocardial apelin production is reduced in humans with left ventricular systolic dysfunction. J Card Fail 2010;16:556-61.
27. Chahal NS, Lim TK, Jain P, Chambers JC, Kooner JS, Senior R. The distinct relationships of carotid plaque disease and carotid intima-media thickness with left ventricular function. J Am Soc Echocardiogr 2010;23:1303-9.
28. Corrado E, Rizzo M, Coppola G, Fattouch K, Novo G, Marturana I et al. An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb 2010;17:1-11.
29. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748-58.
30. Fan Y, Meng S, Wang Y, Cao J, Wang C. Visfatin/PBEF/Nampt induces EMMPRIN andMMP-9 production in macrophages via the NAMPT-MAPK (p38, ERK1/2)-NF-κB signaling pathway. Int J Mol Med 2011;27:607-15.
31. Kostapanos MS, Derdemezis CS, Filippatos TD, Milionis HJ, Kiortsis DN, Tselepis AD et al. Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. Eur J Pharmacol 2008;578:249-52.
32. Kadoglou NPE, Vrabas IS, Kapelouzou A, Sailer N, Lampropoulos S, Kostakis A et al. Impact of atorvastatin on serum vaspin and visfatin levels in hypercholesterolemic patients with moderate cardiovascular risk. Regul Pept 2011;170:57-61.
33. Derdemezis C, Filippatos T, Tselepis A, Mikhailidis D, Elisaf M. Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study. Expert Opin Pharmacother 2008;9:1829-37.
34. Pfützner A, Hanefeld M, Lübben G, Weber MM, Karagiannis E, Köhler C et al. Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk - results from the PIOSTAT study. Horm Metab Res 2007;39:764-8.
35. Ge H, Zhou Y, Liu X, Nie X, Wang Z, Guo Y et al. Relationship between plasma inflammatory markers and platelet aggregation in patients with clopidogrel resistance after angioplasty. Angiology 2012;63:62-6.